Unprecedented developments and therapeutic breakthroughs have been driving the healthcare industry’s growth, with MedTech and healthcare IT the fastest advancing segments. According to a recent survey, 92% of healthcare organizations believe they will achieve revenue growth in 2021, with one in five healthcare organizations considering a merger or acquisition this year.
Healthcare companies are increasing their capital spending and upgrading IT services to adapt to changing industry trends.
As investors rotate toward the healthcare industry to hedge against current market volatility, Wall Street analysts expect the share prices of T2 Biosystems, Inc. (TTOO) and OpGen, Inc. (OPGN), which are currently trading below $10, to double soon.
Click here to checkout our Healthcare Sector Report for 2021
T2 Biosystems, Inc. (TTOO)
TTOO is a Lexington, Mass.-based in-vitro diagnostics company. The company uses its T2MR technology, which enables rapid detection of pathogens, biomarkers, and other abnormalities in a variety of unpurified patient sample types. It’s T2SARS-CoV-2 Panel is designed to detect SARS-CoV-2, the virus that is responsible for COVID-19 infections.
On May 6, TTOO announced the modification of the terms of its existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of multiple products that are being funded under the contract. If all options are exercised, the multi-year contract between BARDA and T2 Biosystems would be valued at up to $69.0 million, allowing the company to improve its healthcare outcomes and strengthen its position in the industry.
TTOO’s total revenue increased 173.3% year-over-year to $6.96 million in its fiscal first quarter, ended March 31. Its product revenue stood at $4.65 million, up 345% from the same period last year.
A $25.23 million consensus revenue estimate for the current year indicates a 39.2% increase year-over-year. The Street expects the company’s EPS to improve 20.5% in the current year versus the last year. TTOO’s shares have gained 1.9% over the past five days.
All four Wall Street analysts that rated TTOO have rated it Buy. The $3.13 median price target indicates a potential 195.3% upside from its $1.06 last closing price. The 12-month price targets range from a low of $2.50 to a high of $3.50.
OpGen, Inc. (OPGN)
OPGN is a precision medicine company that develops molecular information products and services. The company utilizes molecular diagnostics and informatics to help combat infectious diseases.
On August 3, OPGN announced that its subsidiary, Curetis GmbH, and its instrument development and engineering partner have successfully achieved key development milestones in its Unyvero A30 RQ platform program. This should allow the company to expand its product portfolio as well as engage in strategic partnering and licensing discussions to leverage and monetize the A30 RQ platform.
OPGN’s total revenue increased 34.5% year-over-year to $0.83 million in its fiscal first quarter, ended March 31. Its product sales increased 67.3% from the year-ago value to $0.61 million.
Analysts expect OPGN’s revenues to increase 84.9% year-over-year to $7.79 million in the current year. The company’s EPS is expected to improve 46.8% in the current year versus the last year. Shares of OPGN have gained 9.1% over the past five days and 17.7% year-to-date.
The two Wall Street analysts that rated OPGN have rated it Buy. The $5.50 median price target indicates a potential 129.2% upside from its $2.40 last closing price. The 12-month price targets range from a low of $4.00 to a high of $7.00.
Click here to checkout our Healthcare Sector Report for 2021
TTOO shares were trading at $1.21 per share on Wednesday afternoon, up $0.15 (+14.15%). Year-to-date, TTOO has declined -2.42%, versus a 18.38% rise in the benchmark S&P 500 index during the same period.
About the Author: Subhasree Kar
Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...
More Resources for the Stocks in this Article
| Ticker | POWR Rating | Industry Rank | Rank in Industry |
| TTOO | Get Rating | Get Rating | Get Rating |
| OPGN | Get Rating | Get Rating | Get Rating |
